Podcasts about pharmaceutical companies

attorney generals pharmaceutical companies

Play Episode Listen Later Jan 3, 2025 15:18

In this episode, Naim Alkhouri, Mike Betel, Michelle Long and Jeff McIntyre join Jörn Schattenberg and Roger Green to look back at The Liver Meeting 2024. This conversation reviews two sessions promoting healthy livers and asks panelists what they anticipate for #TLM2025. This last conversation starts with Jeff describing the session that moved him most and praising a panel that Mike co-chaired on Lifestyle Management of MASLD and MASH. Jeff spoke on this panel, and he describes the breadth and quality of speakers and topics. While Jeff spoke about social determinants of health, others discussed commercial, regulatory and lifestyle determinants, all intermixed with practical advice on managing patients' lifestyle issues. Finally, he comments on a presentation from Meena Bansal discussing several concurrent posters in the meeting that aligned with the discussion in the session. After Jeff shares the content of the meeting, he comments on the large number of providers and industry executives who attended this patient-centered session. Roger notes a similar distribution of attendees at the Health Livers, Healthy Lives session on building momentum for prevention. In wrapping up the session, Roger does not share another presentation but notes how many modes of action have produced successful Phase 2/3 trial results. He notes that we may have 4-5 different modes of action available five years from now. In the rest of the session, panelists describe what they believe will be different and exciting at #TLM2025. Answers vary, but most focus on advances in drug development and/or NITs.

healthy phase public health promoting looking ahead mash clinical trials patient advocacy drug development patient education fatty liver nits livers pharmaceutical companies healthy lives lifestyle management michelle long global liver institute

Overpowered Pharmaceutical Companies! (Full Show)

The Dom Giordano Program

Play Episode Listen Later Dec 26, 2024 152:47

Overpowered Pharmaceutical Companies! (Full Show) full 9167 Thu, 26 Dec 2024 20:14:08 +0000 9XF7ezhYcsiCX6rj8omDR3ejQVihGG5A news The Dom Giordano Program news Overpowered Pharmaceutical Companies! (Full Show) Weekdays on Talk Radio 1210 WPHT, Dom Giordano talks about what you're talking about. The Dean of Philadelphia Radio and the people's watch-dog, Dom holds elected leaders accountable and gives you a platform to sound off. 2024 © 2021 Audacy, Inc. News False https://player.amperwavepodcasting.com?feed

news dom talk radio overpowered pharmaceutical companies wpht philadelphia radio dom giordano

America's Roundtable with Gerard Gibert | Urgency to Advance Principled Reforms in America | Cut Government Spending | Tax Reform | Healthcare Reform

America's Roundtable

Play Episode Listen Later Dec 21, 2024 29:12

Join America's Roundtable (https://americasrt.com/) radio co-hosts Natasha Srdoc and Joel Anand Samy with host Gerard Gibert, an extraordinary entrepreneur and business leader. Mr. Gibert is also the host of Middays with Gerard on SuperTalk Mississippi . The timely and relevant conversation on America's Roundtable with Gerard Gibert focuses on the issues impacting Americans including the urgency to rein in government spending and the concerns that Congress has failed to put forward a balanced budget. Gerard Gibert also highlights the importance of addressing tax reform and healthcare reform. The conversation on America's Roundtable tackles the ways in which Congress, the incoming Trump administration joined by engaged citizens and taxpayers can address fraud, waste and abuse impacting the Department of Defense (DOD). "In fiscal year 2024, DOD underwent its seventh financial statement audit, and again received a disclaimer of opinion. For the seventh time consecutively, auditors were unable to “obtain sufficient, appropriate audit evidence to support an opinion.” GAO continues to designate DOD's financial management and business systems modernization efforts as high risk because of pervasive deficiencies in the department's business processes, internal controls, financial reporting, and financial management systems." — House Committee on Oversight and Accountability, December 11, 2024 In 1986, Gerard Gibert founded Venture Technologies, a technology and cloud services provider. As CEO of Venture, Gibert engineered numerous mergers and acquisitions of strategic targets, catapulting Venture to national prominence as a technology solutions provider. Initially funded at $189,000, Venture was sold for $92 million in 2019. Mr. Gibert serves on a variety of boards dedicated to growing Mississippi's economy. That list includes the Madison County Economic Development Authority, Madison County Business League and Foundation, Innovate Mississippi, Empower Mississippi, and the Mississippi Lottery Corporation. Gerard Gibert also serves on the executive advisory board of International Leaders Summit and is co-chair of the U.S.-based think tank's American Leadership Task Force advancing principled reforms. americasrt.com (https://americasrt.com/) https://ileaderssummit.org/ | https://jerusalemleaderssummit.com/ America's Roundtable on Apple Podcasts: https://podcasts.apple.com/us/podcast/americas-roundtable/id1518878472 X: @grgibert @ileaderssummit @NatashaSrdoc @JoelAnandUSA @supertalk America's Roundtable is co-hosted by Natasha Srdoc and Joel Anand Samy, co-founders of International Leaders Summit and the Jerusalem Leaders Summit. America's Roundtable (https://americasrt.com/) radio program - a strategic initiative of International Leaders Summit, focuses on America's economy, healthcare reform, rule of law, security and trade, and its strategic partnership with rule of law nations around the world. The radio program features high-ranking US administration officials, cabinet members, members of Congress, state government officials, distinguished diplomats, business and media leaders and influential thinkers from around the world. Tune into America's Roundtable Radio program from Washington, DC via live streaming on Saturday mornings via 65 radio stations at 7:30 A.M. (ET) on Lanser Broadcasting Corporation covering the Michigan and the Midwest market, and at 7:30 A.M. (CT) on SuperTalk Mississippi — SuperTalk.FM reaching listeners in every county within the State of Mississippi, and neighboring states in the South including Alabama, Arkansas, Louisiana and Tennessee. Listen to America's Roundtable on digital platforms including Apple Podcasts, Spotify, Amazon, Google and other key online platforms. Listen live, Saturdays at 7:30 A.M. (CT) on SuperTalk | https://www.supertalk.fm

Inside BC's plan to sue pharmaceutical companies

Mornings with Simi

Play Episode Listen Later Dec 2, 2024 10:20

Guest: Niki Sharma, Attorney General of British Columbia Learn more about your ad choices. Visit megaphone.fm/adchoices

The Case for Ozempic, Weed's Risks, and Big Pharma Conspiracies | Mike Israetel

BigDeal

Play Episode Listen Later Nov 12, 2024 117:44

Record your first video with Riverside - https://creators.riverside.fm/Codie - and use code CODIE for 15% off an individual plan. Codie Sanchez and Dr. Mike Israetel delve into the complexities of health, fitness, and obesity. They explore the societal and genetic factors contributing to the obesity epidemic, the role of convenience foods, and the impact of medications like Ozempic on appetite and weight management. The discussion also touches on personal responsibility in dietary choices and the cultural perceptions of body image and attraction. This conversation delves into various themes surrounding self-defense for women, the effects of alcohol and cannabis on health, the future of fitness through drugs and genetic enhancements, and the ethical considerations of pharmaceutical companies. The discussion highlights the importance of understanding personal safety, moderation in alcohol consumption, the complexities of cannabis use, and the potential for future advancements in health and fitness through scientific innovations. In this conversation, the speaker delves into various themes surrounding the pharmaceutical industry, corporate responsibility, and the importance of long-term thinking in business. They discuss the competitive nature of the pharmaceutical sector, the alignment of incentives within corporations, and the impact of regulatory environments on economic outcomes. The conversation also touches on the purpose of corporations, teamwork, and the significance of a cooperative mindset in achieving success. Hope you guys enjoy! Checkout More from Codie: Youtube: https://www.youtube.com/@CodieSanchezCT Instagram: https://www.instagram.com/codiesanchez/ TikTok: https://www.tiktok.com/@realcodiesanchez Free newsletter: https://contrarianthinking.biz/3XWLlZp Biz buying course: https://contrarianthinking.biz/3NhjGgN Resibrands: https://resibrands.com/ CT capital: https://contrarianthinking.biz/4eRyGOk Main st hold co: https://contrarianthinking.biz/3YfGa8u

How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks

Investing Insights

Play Episode Listen Later Sep 27, 2024 14:33

Karen Andersen, biotechnology strategist for Morningstar Research Services, discusses what GLP-1 drugs' demand means for the biopharma industry's five-year outlook. And whether the weight-loss drugs pose a threat to snack food stocks.Why GLP-1 Drugs Are in Demand Competition Between Novo Nordisk and Eli LillyHow Expanding the Conditions GLP-1 Drugs Treats Could Influence Insurance CoverageAre Weight Loss Drugs a Threat to Snack Food Stocks?Big Pharma's Looming Patent CliffHow Medicare Negotiations Impact the Pharmaceutical IndustryWhat is a Biologic Drug?Upcoming Innovations in the Pharmaceutical IndustryWhich BioPharma Drugs Do We Expect to Contract?Big Pharma's Five-Year OutlookBiopharmaceutical Stock Picks Read about topics from this episode. 2024 Biopharmaceutical Industry LandscapeObesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk? Investment Opportunities in the Biopharma Industry Obesity Drug Market: The Next Wave of GLP-1 Competition What to watch from Morningstar.Is the Fed's Plan to Avoid a Recession Working? Don't Overlook These Crucial Parts of Your Retirement PlanBoating Season Is Over, but Don't Overlook These Recreational Vehicle Stocks5 Ways to Improve America's Retirement Savings Read what our team is writing:Karen Andersen Ivanna Hampton Follow us on social media.Facebook: https://www.facebook.com/MorningstarInc/X: https://x.com/MorningstarIncInstagram: https://www.instagram.com/morningstar... LinkedIn: https://www.linkedin.com/company/5161/

How Pharmaceutical Companies Control the Narrative with Sharyl Attkisson

The Illusion of Consensus

Play Episode Listen Later Sep 7, 2024 65:41

In this conversation with Sharyl Attkisson, I, Dr. Jay Bhattacharya, delve into how pharmaceutical companies manipulate media narratives through their advertising power, causing journalists to self-censor. We also examine how regulatory agencies like the FDA and CDC are influenced by pharmaceutical funding, which undermines public trust in their decisions. This episode highlights the pressing need for critical, independent thinking in healthcare to protect public interests. Receive Exclusive Episodes & Q&A Content by joining our Substack Community: https://www.illusionconsensus.com/

narrative cdc fda pharmaceutical companies sharyl attkisson

The Tudor Dixon Podcast: Parents, Politicians, and the Path Forward to Protect Our Kids

The Tudor Dixon Podcast

Play Episode Listen Later Sep 5, 2024 25:55 Transcription Available

In this episode, Tudor, along with Kyle Olson and Sara Broadwater, discuss the recent school shooting in Georgia. Tudor expresses her shock and concern as a parent, emphasizing the emotional toll on families and the need for deeper conversations about school safety, mental health, and gun access for minors. Kyle highlights Michigan's initiatives to address youth mental health and questions the effectiveness of reactive laws. The episode underscores the urgency of a comprehensive approach to protect children, advocating for education, accountability, and proactive measures to prevent future tragedies. The Tudor Dixon Podcast is part of the Clay Travis & Buck Sexton Podcast Network. For more visit TudorDixonPodcast.comSee omnystudio.com/listener for privacy information.

#461: Turning the Tide on the American Health Crisis

Vitality Radio Podcast with Jared St. Clair

Play Episode Listen Later Aug 31, 2024 30:37

Americans are sicker than ever. 66% of adults and kids have a chronic illness. It hasn't always been this way. Something has changed in the last 50 years to cause this decline in our health. There are few people out there talking about this but over the last couple of weeks there have been some developments that have brought this issue more to the forefront. On this episode of Vitality Radio, Jared shares some shocking statistics that have gotten some recent attention thanks to a few important interviews. You'll hear just how serious the state of our health is and more importantly, what we can do about it. There are big changes that need to be made within our government and the industries to reverse this decline, but the solution truly starts with the choices we make at home.Additional Information:Calley & Casey Means: How Big Pharma Keeps You SickGood Energy - by Casey & Calley Means (book)RFK Jr. on Tucker#458: Supplements Under Attack: How This Affects You and Why You Should Care#456: What Is Behind the Rise in Food Allergies and Autoimmune Disease? With Gerald Roliz#442: Against the Odds - A Story of Hope and Healing with Suzanne Bates#264: Emotional Vitality: Jen's Story Part 1 - From Addiction and Mental Illness to Vitality (part 1 of series)Visit the podcast website here: VitalityRadio.comYou can follow @vitalityradio and @vitalitynutritionbountiful on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Please also join us on the Dearly Discarded Podcast with Jared St. Clair.Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.

S5 - E24.2 - EASL Congress Six Weeks Later: Mathieu Petitjean's Key Implications

congress companies phase fda implications mash mathieu oncology diagnostics six weeks biopsies drug development weeks later mre hcc hepatology fibrosis pharmaceutical companies

Play Episode Listen Later Aug 7, 2024 10:58

In the second half of Roger Green's interview with PharmaNest Founder and CEO Mathieu Petitjean, Matt discusses the implications of his key EASL Congress takeaways for PharmaNest. Matt starts this discussion with a simple question: Will biopsy-based analyses become part of a surrogate endpoint? As he points out, they are not today, and creating the necessary data might require a significant effort. If not, they are unlikely to remain relevant to the large, Phase 3 trials. Regardless of the answer to this question, Matt believes digital pathology will still be important in pre-clinical work and other efforts to define underlying liver structures and faults better. Also, he notes, digital pathology is valuable in an array of other liver diseases and in non-hepatological markets, notably including pathology. One way or another, he is confident PharmaNest will continue to make contributions to hepatology and grow as a business.

Carol Tavris - Mistakes Were Made But Not By Me

The Innovation Show

Play Episode Listen Later Jul 31, 2024 75:13

Carol Tavris - Mistakes Were Made But Not By Me The Psychology of Self-Justification with Carol Tavris In this episode, Aidan McCullen interviews Carol Tavris, co-author of 'Mistakes Were Made (But Not by Me),' to explore the intricacies of cognitive dissonance, self-justification, and memory. They investigate why humans find it difficult to admit mistakes, even in the presence of irrefutable evidence. Through numerous case studies and real-world examples, they discuss the implications of these psychological mechanisms in areas as varied as personal life, law enforcement, and political decision-making. The conversation tackles how these insights can apply to everyone from parents and judges to business leaders and law enforcement, emphasizing the significance of humility, critical thinking, and the human tendency to rewrite personal histories to fit current beliefs. 00:00 Introduction to Self-Justification 01:14 Welcoming the Author: Carol Tavris 02:17 The Premise of the Book 03:06 Understanding Cognitive Dissonance 08:44 Memory and Self-Justification 14:43 Confabulations and False Memories 23:02 The Pyramid of Choice 32:42 Law Enforcement and Wrongful Convictions 37:58 The Importance of Correcting Interrogation Methods 38:33 The Impact of Miscarriages of Justice 38:55 Examples of Recognizing Mistakes 39:52 The 1980s and 90s Hysteria Over Child Abuse 40:21 The McMartin Daycare Scandal 41:06 Flawed Child Interrogation Techniques 42:58 A Case of Misunderstanding: Daddy's Pee Pee 44:53 The Emotional Toll of False Convictions 47:39 The Pyramid of Entrapment and Justification 48:48 The Influence of Bias in Decision Making 50:32 The Role of Pharmaceutical Companies in Medicine 52:06 Moral Choices and Life Decisions 54:55 Understanding and Living with Cognitive Dissonance 01:03:17 The Power of Admitting Mistakes 01:06:58 The Allure of Victim Narratives 01:08:40 Alien Abductions and Hypnagogic States 01:14:17 The Importance of Understanding Human Frailties Find Carol here: That Sarah Silverman interview: Carol's books: psychology, cognitive dissonance, self-justification, memory, mistakes, humility, ethics, law enforcement, interrogation, wrongful convictions, trauma, alien abductions, confirmation bias, leadership, decision making, self-concept, Carol Tavris (author), Aidan McCullen (host), Elliot Aronson (co-author), Leon Festinger (researcher on cognitive dissonance), James Thurber (author of The Wonderful O), Richard Feynman (scientist and quote source), Mary Carr (memoirist), Joseph Allen (wrongfully convicted), Ronald Reagan (Bitburg cemetery incident), Shimon Peres (comment on Reagan's mistake), Sarah Silverman (Louis C.K. controversy), Louis C.K. (comedian involved in controversy), Jeffrey Cohen (research on political bias), Lee Ross (naive realism), John Mack (psychiatrist on alien abductions), Susan Clancy (researcher on alien abductions), Rich McNally (memory scientist), Antonin Scalia (Supreme Court Justice), Clarence Thomas (Supreme Court Justice), Auburn Blooming (oncologist and co-author)

S5 SPECIAL 3 - Reviewing EASL Congress: Louise Campbell 2

europe congress reviewing cap surfing mash collectively cpg diagnostics drug development tirzepatide pharmaceutical companies louise campbell

Play Episode Listen Later Jul 20, 2024 20:47

This week, Surfing the MASH Tsunami looks back on interviews Roger Green conducted during the EASL Congress itself. This conversation with SurfingMASH co-host and Tawazun Health Founder and Clinical Director Louise Campbell took place on the last day of the Congress.This conversation centered on three major topics addressed at the EASL Congress, each of which made Louise "quite enthusiastic."The first of these was the presentation of the new EASL/EASD/EASO Clinical Practice Guidelines and their practical implications (Season 5 Episode 21). Louise described this session as having "blown her mind" with its forward-thinking style and recommendations. She termed it a "leap of faith" that we all need to think differently about diabetes and obesity given how quickly incidence is growing. Her favorite items? The guidelines mentioned resmetirom even before it was approved in Europe. Also, the guidelines described ways to use several drugs that have not been approved for MASLD to treat patients with other metabolic conditions that are linked to MASLD. Louise also expressed enthusiasm at which three organizations partnered on this document.Roger suggested that this aligned broadly with the various drug presentations in the Late Breaker and General sessions. Collectively, those presentations highlighted an array of drugs with different modes of action and strengths across the metabolic continuum. More generally, the two agreed that we are looking at a world where, in just a few years, we will have multiple drugs, most with unique modes and all with specific patient targets.Roger asked whether Louise believes that over time, the diagnostic focus would stay with liver stiffness and CAP or switch to in-office PDFF. Louise suggested that in a world where clinical trials may not require biopsy, it would be difficult to build a sufficiently robust data set for any new tests.

Insight Unpacked S2E4 | The Bargain That Fuels Big Pharma

Kellogg INSIGHT

Play Episode Listen Later Jul 15, 2024 26:04

What will we pay for the next groundbreaking drug? In episode 4 of our 5-episode series, “Insight Unpacked: American Healthcare and Its Web of Misaligned Incentives,” we explore the trade-off at the heart of pharmaceutical innovation. On this episode, we hear from Kellogg faculty members Amanda Starc and Craig Garthwaite, as well as Boston University School of Law's Kevin Outterson. Visit the episode page for supplementary materials.

law drugs big pharma pharma kellogg fuels bargain antibiotics pharmaceuticals unpacked boston university school antibiotic pbm pbms drug companies pharmaceutical companies pharmacy benefit managers jardiance entresto

Navigating the AI Revolution: Zachary Levi on The Intersection of Health, Media, and Tech

The Darin Olien Show

Play Episode Listen Later Jun 26, 2024 97:55

Are we headed toward a future controlled by AI? In today's episode of the Darin Olien Show, Zachary Levi and I discuss the potential implications of rapidly advancing artificial intelligence (AI) and its impact on society, jobs, and our way of life. As AI continues to progress at an unprecedented pace, it's crucial for us to be aware of the potential consequences, such as widespread job displacement across industries like entertainment, and the importance of creating intentional communities that prioritize human connection, well-being, and purpose. Levi shares his insights on the need for individuals to take responsibility for their own healing and personal growth to become more effective agents of positive change in the world. He emphasizes the significance of self-love, addressing traumas, and exploring various therapeutic modalities, including plant medicines and psychedelics, to support mental and emotional well-being. To learn more about the future of AI, the importance of intentional communities, and the transformative power of personal growth, be sure to listen in. Zachary Levi is known for his work in "Chuck" and "The Marvelous Mrs. Maisel," as well as films like "Shazam!” and "American Underdog,” A true champion of mental wellness, He is committed to helping others who deal with the challenges that life presents, bringing people back to the center of health and happiness. What we discuss… (00:00) Uncovering Truths Through Media (07:31) The Influence of Pharmaceutical Companies (15:00) Exploring Human Ego and Capitalism (25:05) The Impact of AI on Employment (29:00) The Ethics of Technology and Leadership (38:33) Navigating the Impact of AI (52:22) The Future of AI in Entertainment (59:46) Building a Better Hollywood and Community (01:10:46) Creating Intentional Communities With Purpose (01:18:20) Prioritizing Self-Improvement and Healing (01:31:51) Upcoming Film Projects and Historical Stories (01:35:35) Creating Thriving Communities Through Film …and more! Don't forget: You can order now by heading to darinolien.com/fatal-conveniences-book or order now on Amazon. Thank you to our sponsors: Bite: Go to trybite.com/DARIN20 or use code DARIN20 for 20% off your first order. Therasage: Go to www.therasage.com and use code DARIN at checkout for 15% off Vivo Barefoot: Get 20% off your first Vivobarefoot order with DARIN20 at www.vivobarefoot.com Branch Basics: Save 15% on your Starter Kit when you use code DARIN at www.branchbasics.com. Find more from Darin: Website: https://darinolien.com/ Instagram: https://www.instagram.com/Darinolien/ Book: https://darinolien.com/fatal-conveniences-book/ Down to Earth: https://darinolien.com/down-to-earth/ Find more from Zachary Levi: Book: Radical Love Instagram: @zacharylevi

S5 - E20 - Lessons From EASL Congress 2024: Exciting Advances in Drug Development

The Illusion of Consensus

Play Episode Listen Later Jun 20, 2024 57:35

00:00:00 Surf's Up, Season 5 Episode 20Naim Alkhouri and Mazen Noureddin join co-hosts Jörn Schattenberg and Roger Green to discuss major drug development stories from the EASL Congress 2024. They pay tribute to Stephen Harrison and proceed to groundbreakers.00:08:16 - Presentations on ResmetiromMazen shares a paper he presented looking at resmetirom dose-response. The 100mg dose performed better than the 80mg dose. Jörn notes that the most important element of the study might be the demonstrated 36-month effect. 00:14:19- Implications of Different Analytical Modes Naim compares different modes of analysis. Intent to Treat, which treats all non-completers as failures, will produce lower rates of response than a "completer" or "modified Intent to Treat" analysis, which either eliminates non-completers or assigns them placebo-level response. 00:16:12 - The "Twin-Cretins"Jörn coined the name "Twin-cretins" for agents with GLP-1 agonism plus another incretin effect. Tirzepatide is a GLP/GIP while survodutide, pemvuditide, and efinopegdutide, are GLP/glucagons. Naim reviews the tirzepatide late-breaker presentation, which showed high rates of MASH resolution, but, as a completer analysis, might not have proven whether a GLP/GIP can achieve significant fibrosis regression. Naim notes that Stephen doubted strongly this was possible, but that bariatric surgery's effect creates a paradox. Mazen concurs, and states he is more confident in the GLP/glucagon agents. Jörn agrees. 00:23:09 - Implications of widespread GLP useRoger asks how widespread prior patient use of incretins will affect prescribing. Naim states that many of his Rezdiffra MASH patients have been on GLP-1 already. He describes a key difference between the three GLP/glucagon agents in development. 00:24:20 - The previous GLP/glucagon studiesNaim expresses his excitement about glucagon agents in general. He mentions that the efinopegdutide study included a semaglutide cell, which showed a further reduction in liver fat compared to the GLP-1 agent. 00:26:44 - Safety of survodutide in cirrhosisJörn comments on the high level of tolerability in the survodutide trials. Mazen shares his high hopes for GLP/glucagons and the triple agents. He reviews survodutide data from the NEJM article. 00:29:41 - FGF-21s, starting with efrux data Focus shifts to FGF-21s. Mazen shares data from the efruxifermin late-breaker, a 96-week, triple biopsy study showing dramatic, sustained one- and two-level fibrosis improvement. Jörn notes the design demonstrates durability, which Roger finds particularly encouraging given the pegbelfermin experience. Naim adds that a sustainable two-stage drop in fibrosis might position FGF-21 as induction therapy before long-term oral maintenance. 00:35:28 - Is a drug-based MASH "cure" possible? Mazen wonders whether sustained FGF-21 efficacy might return livers to their "normal" state, almost like a "cure." Jörn briefly discusses pegozafermin, and Mazen notes that a third FGF-21 is in development. 00:42:22 - Wrap-up The panel covers three other agents: the FASN inhibitor, denifenstat, Ionis's DGAT-2 antisense inhibitor, ION224, and Takeda's TAK-227, a TG2 inhibitor, plus the results of SPECIAL, a study evaluating the effect of bariatric surgery on people with cirrhosis. After these, Roger asks Mazen and Jörn what they consider likely to be the biggest story at AASLD in November. 00:53:03 - Question of the Week Given this discussion, Roger asks what are likely to be the three most prescribed medications for MASH five years from now. 00:53:36 - Business Report The next EASL Congress review episodes, how to attend recording sessions live, and a vault discussion from last year's EASL Congress wrap-up.

Exposing the truth behind FDA's Drug Approval Process ft: Kim Witczak

Play Episode Listen Later Jun 19, 2024 60:39

Join Professor Jay Bhattacharya and special guest Kim Witzak for an insightful conversation on patient advocacy and drug safety. Kim shares her deeply personal story, revealing how her husband's tragic experience with antidepressants propelled her into a mission for change. Together, they uncover the flaws in the FDA's drug approval process and the critical need for transparency and real-world safety measures. Through Kim's experiences and insights, discover the power of collective action and the importance of amplifying patient voices for a healthier future. Let us know your thoughts and ideas on these takes in the comment section below! Receive Exclusive Episodes & Q&A Content by joining our Substack Community: https://www.illusionconsensus.com/ Sponsors - Alcami Elements :https://www.alcamielements.com/ Receive 10% OFF first order or 30% OFF subscription order using code: ILLUSION -Brownstone institute: https://brownstone.org/ Timestamps 00:00 Introduction & Kim's Background 14:06 Flaws in the FDA's Drug Approval Process 24:16 Balancing Patient Access and Safety Concerns 36:45 The Influence of Pharmaceutical Companies on the FDA 41:23 The Impact of Direct-to-Consumer Advertising 49:46 The Handling of COVID Vaccines: Lack of Debate and Pushback 58:14 The Power of Regular People: Speaking Up for Change

power change debate influence impact receive drug fda exposing approval truth behind flaws pharmaceutical companies

Fines Levied on Pharmaceutical Companies Due to Fraudulent Marketing and the Negative Impacts of These Fraudulent Activities

The Real Truth About Health Free 17 Day Live Online Conference Podcast

Play Episode Listen Later Jun 1, 2024 13:23

marketing negative impacts activities fines fraudulent pharmaceutical companies

The Manipulative Marketing Strategies of Pharmaceutical Companies

The Real Truth About Health Free 17 Day Live Online Conference Podcast

Play Episode Listen Later May 28, 2024 22:19

strategy marketing strategies manipulative pharmaceutical companies

James Duboff: Genomics 101 - How do pharmaceutical companies use genomic data for drug discovery?

The G Word

Play Episode Listen Later May 22, 2024 13:10

In this explainer episode, we've asked James Duboff, Strategic Partnerships Director at Genomics England, to explain how genomic data can be used in drug discovery. You can also find a series of short videos explaining some of the common terms you might encounter about genomics on our YouTube channel. If you've got any questions, or have any other topics you'd like us to explain, feel free to contact us on info@genomicsengland.co.uk. You can read the transcript below or download it here: https://files.genomicsengland.co.uk/documents/Podcast-transcripts/How-do-pharmaceutical-companies-use-genomic-data-for-drug-discovery.docx Naimah: How do pharmaceutical companies use genomic data for drug discovery? Today, I'm joined by James Duboff, a Strategic Partnerships Director here at Genomics England, to find out more. So James, first of all, what is genomic data, and how does this relate to our genes? James: Let's start with a simple explanation of what we mean by genomic data and our genes. So, every cell in our body contains a complete copy of our genome. Now, genome is kind of a mini instruction manual that describes exactly how to make you. Now, those instructions are written in a language called DNA, which is over 99 percent identical in every single human on the planet, so you and I are actually genomically very, very similar. The differences, however, are called variants, and they're what make us unique. Now, some of those variants can actually be very dangerous, and they can code for things like rare genetic diseases or even cancer. So, we need to read in detail exactly what's going on in your DNA and in your genome to see where changes are and where those variants really are, and we do this by sequencing the genome. So, if you get a DNA sequence, that's effectively an electronic readout of your genomic data, which is your genome in computational form. Now, understanding that and working with that is still a relatively new field, so what we try and do is connect the genomic data, your genome, with health information, such as hospital records and what you're presenting with in clinic, if you're in a patient setting, and look at those together to give context to those variants in the genome. So, genomic research is actually where we look at how genes and physical outcomes could be linked. So thinking of, you know, biology and physiology term, what does a variant exactly do and how might it cause a disease. Naimah: You mentioned both the genome and whole genome sequencing, and if our listeners aren't too sure exactly what they are, they can listen to some of our other explainer episodes with Greg Elgar, who explains these concepts. So James, next could you tell me why are pharma and biotech companies interested in genomic data? James: Ultimately, pharma and biotech companies are interested in genomic data because that really tells them what's going on within the blueprint or that mini instruction manual of an individual. So, pharma and biotech have dedicated research teams that focus on genomic research, and they look through genetic databases across the world, such as Genomics England and others, to really understand the role of the genome in their target disease areas. By looking at those, that helps them develop new drugs and tools to specifically diagnose, treat and also even cure these diseases. Naimah: So, how exactly do they do that? Can you explain it in some simple steps? James: I think there are four key areas that they need to focus on. So, starting with the first, where, whereabouts on a genome should they focus? Now, the way that a pharma company would do this, or any researcher really, is by taking two populations of people. So, you'd take a population who have a known disease, and you'd compare that to people without. Now if you're looking at the genomes of people with the disease and those without the disease, you can kind of play spot the difference between those two, and understand whereabouts on the genome variants appear for the disease population and not for the healthy or undiseased control group. Now, when you do that, you can kind of pinpoint exactly whereabouts you see variants only in that patient population. That helps you identify your target, and that's known as target identification, which is essentially pinpointing that spot on the genome that's linked only to the disease. Once you know that, you can use that as a potential target for a new drug. So, once you've found that variant, the next step was, what does that variant do? Is it potentially overproducing something? Is it activating a promoter and therefore making more and more and more of a gene product that, you know, might be toxic inside a person if you have too much? Even too much of a good thing could be a bad thing. So, is that the case? Or does that variant cause an underproduction or something to just be not actually made by your body at all? So, if that variant kind of interferes with a piece of genetic code, it could stop that gene from producing anything, and therefore you might be effectively detrimented and deprived of that particular gene product. And both of those, an overproduction or an underproduction, could lead to a disease. So, to understand that in more detail, you might need to look at gene products as well. The next step, once you know whereabouts in the genome you're looking and what exactly a variant does, the next step really for a pharma company is how could you fix that. So, if you're looking at too little of something – so, if a variant stops a gene from actually developing into a gene product then you might need a drug to boost or to compensate for that, so potentially a supplement or having some kind of drug that can get the body to make more of that product. If on the other hand your body is making too much of something in a way that could be toxic, you kind of want a drug to reduce those levels, so a drug that could potentially breakdown that gene product so that you don't have too much of it, or stop it from working effectively, so that it doesn't seem as if you have too much of it, or otherwise prevent it being made altogether. Now, one example of this prevention is actually a gene silencing drug, or an ASO, as they're effectively known, which can be used as a genetic mask. So, that sits on top of a gene and hides it, so the body can't actually make that dangerous varied gene product. Now, if you're going to make something like that, you need to be absolutely sure that masking that entire gene and stopping even a varied form of it isn't dangerous, so that last step really is making sure that your drug is safe and wouldn't cause any other issues. So, traditionally, that would have been done using animal models as kind of a surrogate organism, but now using genomic databases, you can use human genomics as kind of real world examples of applying say a genetic mask and hiding an entire gene or genetic section, and you can look through genetic databases to have a look for individuals who are alive and hopefully healthy in the population, who don't express a certain gene. So, if you can find people who are healthy, who don't have that gene or have variants that stop that gene from being produced, you kind of can be confident that you can make a drug to cover that and it would be considered safe. Naimah: Okay, so that's really interesting. So, what you're saying is, by using human genomic data, we can test the impact and safety of gene targeting drugs directly in humans. James: Yes, exactly. So, you can ask that question of would hiding that gene entirely cause any other health issues or any adverse effects really from a drug that hides it. And the really useful thing about that is that we'd know the impact of a gene targeting drug before you'd say start a clinical trial, so that really stacks the odds in your favour of the drug working safely, which is really powerful for a drug company that would otherwise invest a lot of money in a clinical trial that could be a risky endeavour for the company and also for participants. So, this is very useful for patients, and also fundamentally it's a lot more useful for a company to be assessing safety using humans and human genomics directly as opposed to using a surrogate organism like a mouse, which many people would argue is not a good reflection of what would happen in humans. Naimah: Can you tell me briefly if genomics can be applied to other stages of the drug delivery pipeline? James: Yes, in fact genomics can be applied all along the drug discovery and development R&D pipeline. So, as an example, biomarker identification. A biomarker is a biological product or a chemical signal that's associated with a disease, that you can find and monitor inside the body. So, you can look at an increase in that biomarker or a decrease in that to monitor whether a drug is working as you'd expect. Is the drug increasing levels of something being produced, or is it decreasing that product being produced? And you can use that to understand whether it's possible to potentially develop that treatment, would that treatment actually work. So, that's really important in monitoring drug impact and also understanding clinical endpoints for a trial. You can also look at biomarker identification to look for genes and variants that are associated with a disease that could help you understand who best to enrol in a clinical trial. So, clinical trial recruitment is another key area, where if you involve the genome in your enrolment criteria, you can essentially just recruit the most suitable people where you know the drug will work best, and also you're sure that the drug would be most safe and effective at treating their condition. And then actually to go a step further on the clinical trial point, clinical genomic datasets are actually really useful, if you think about it, in the opportunity to recontact participants too where they've consented. So, what I mean by that is, a pharma company could directly find and recruit optimal patients with either a rare disease or a cancer where their drug would help most, based solely on their genome, and that's a really, really exciting point, because that offers the opportunity for pharma to both develop a drug based on that genomic dataset, but also then deliver the drugs to treat those same exact people. Naimah: So, how do pharmaceutical companies access this data? James: Well, there are different datasets, and each different dataset has a different population within those, and each of them have their own consent models and governance rules on how that data can be used and who can access it, and how they access it. So, some of these datasets just hold genomic data, while others would have additional biochemical data and also health information potentially on participants. So, depending on the different types of data, there'll be different access limitations and restrictions. So, some entities and some datasets can be simply downloaded, and that could be very useful for pharma and biotech companies, because that means that they could use them inhouse. Other datasets and groupings of genomic data and libraries of sorts would operate a TRE or an SDE model, so that stands for a trusted research environment or a secure data environment, and these are essentially – you could consider them as libraries, like a reading library, where you can come in and read the books but not take out those books, or genomes in this case. Naimah: Can you tell me, what impact does the use of genomic data for drug discovery have on the public or patients? James: Oh, there's huge impact on drug discovery, and ultimately genomic research really helps drug companies make better treatments for patients and the public. So, we've already seen the benefits of genomics used in drug discovery, and I think we will do more and more as DNA sequencing is used more in clinic, and also that's going to keep happening the more cost keeps dropping, which is making genomic medicine really and genomic healthcare increasingly feasible at scale. So, 20 years ago, it cost over £100 million and it took years to sequence a genome, but today you can sequence a genome within a few hours for under £1,000. Naimah: What are the benefits of having your genomes sequenced in a healthcare setting? James: Ultimately, genomics enable a faster and more accurate diagnosis. That enables early intervention, which can really maximise the treatment impact and improve outcomes. So, what I mean by early intervention, if you can give a drug before someone shows symptoms then you could prevent them ever getting the disease, so that's moving towards preventative medicine, which is really exciting and absolutely enabled through genomics. So, genomics really help pharma companies make also better drugs and target the underlying disease directly rather than just addressing symptoms, so this helps them make more effective and safe treatments to really improve overall outcomes for patients. Another thing to think about is that some drugs are already on the market but used for different reasons. Genomics can help pinpoint the root cause of that disease within a genomic setting, so that can highlight repurposing opportunities for existing drugs. Now, existing drugs are those that have already been proven safe in humans and approved for use, albeit potentially in a different setting. Now, if a drug could be shown by genomic research to be targeting the same root cause within the same biological pathway, they could very easily be repositioned and applied in an entirely new disease. So, I guess to finish, through genomics, drug development can help us move towards precision healthcare, and by that I mean making targeted treatments for specific patients. That will be far more effective and have significantly fewer side effects. In the case of participants in clinical genomics sequencing programmes open to researchers, that also means matchmaking opportunities for companies to diagnose and treat unique patients. In the case of ultra rare conditions, that means they can create a treatment specifically for that patient and then work with their doctors to deliver the brand new drug just to them, to ultimately save lives. Naimah: That was James Duboff explaining how pharmaceutical companies can use genomic data for drug discovery. If you'd like to hear more explainer episodes like this, you can find them on our website at www.genomicsengland.co.uk. Thank you for listening.

data dna genomics aso drug discovery sde pharmaceutical companies genomics england james yes james oh james well

ER Doc on Schmovid & Childhood Waxeens w/ Dr. Ira Price | EP322

The Mental Wealth Podcast

Play Episode Listen Later May 20, 2024 70:01

Episode Highlights: discourse, diversity of thought, medical establishment, COVID-19, mental health, pharmaceutical companies, physicians, immunizations Summary: Welcome to this Monday edition of the Awake & Winning Podcast where Kaylor and Dr. Ira Price cover a wide array of topics in their discussion, ranging from the delicate balance between chaos and positivity in the world and Dr. Price's journey in medicine which highlights the importance of open discourse, embracing diverse perspectives, and shedding light on the challenges within the medical establishment. Their conversation delves into the complexities of the COVID-19 pandemic, addressing the overlooked issue of mental health and its profound impact on society. Dr. Price also touches on the role of pharmaceutical companies in healthcare, stressing the need for physicians to question the status quo and advocate for change. While briefly touching on immunizations and vaccines, this conversation underscores the significance of seeking reliable sources of information and making informed decisions in navigating healthcare choices. Takeaways: The positivity and the awakening that is happening despite all of the chaos in the world Emphasizing the importance of open discourse and diversity of thought in both medicine and society The medical establishment faces challenges in bridging the gap between medicine and the community The COVID-19 pandemic has highlighted the need for balanced decision-making and consideration of the risks and benefits of various approaches The neglect of mental health during the pandemic had significant consequences and the importance of addressing psychological well-being alongside physical health Pharmaceutical companies are primarily marketing companies focused on selling their products Physicians should question and push back against the establishment when necessary, advocating for the best interests of their patients When it comes to immunizations, consider the benefits and risks, rely on trusted sources, and make informed decisions If you enjoyed the episode, please be sure to take a screenshot and share it out on Instagram and tag @thekaylorbetts. Also, please make sure to give us a review and a five star rating if you're loving what we are doing! _____________________________ RESOURCES & LINKS MENTIONED IN THIS EPISODE: Instagram | https://www.instagram.com/dr.iraprice/ TikTok | https://www.tiktok.com/@dr.ira Websites | https://driraprice.com/ Podcast | The Higher Estate Podcast on Apple Podcasts _____________________________ SPONSORS: Truly Tallow | https://www.trulytallow.com/ Use code “SUNNYBALLS10” at checkout for 10% off your order _____________________________ IMPORTANT UPDATES: Check out the Awake & Winning Website | https://awakeandwinning.com/ Join the Awake & Winning Life AW-cademy | https://theawlife.com/ Join the Awake & Winning Business AW-cademy | https://theawbiz.com Join the Awake & Winning POD-cademy | http://yourwinningpodcast.com/ Follow Kaylor on Instagram | https://www.instagram.com/thekaylorbetts/ ____________________________

covid-19 tiktok mental health pandemic doctors price childhood physicians websites emphasizing discourse pharmaceutical immunizations er doctor kaylor pharmaceutical companies er doc medical establishment summary welcome

Longevity Expert: We can reverse our age, people just don't want to believe it.

Aesthetics Mastery

Play Episode Listen Later Apr 27, 2024 47:33

If you want to learn how to introduce longevity into your clinic but feel overwhelmed with conflicting information then I'm hosting a webinar with Dr Nichola on the 28th May especially for clinicians to help you get started. Sign up to be notified when webinar registration goes live here. In this episode Tim dives deep into Dr Nichola's background in cellular aging and drug development to understand how she has become a longevity expert and entrepreneur. Tim Uncovers Why She Ditched Drug Development and Reveals the crazy Truths that Pharmaceutical Companies don't want you to know. They also dicsuss the revelation that it IT possible to reverse our biological age but why so many people out there are skeptical to believe it.Follow Dr Nichola on Instagram: https://www.instagram.com/drnicholaconlon/Learn more about Nuchido here: https://nuchido.com/Follow Dr Tim on Instagram here: https://www.instagram.com/drtimpearce/ Follow Dr Tim on Youtube here: https://www.youtube.com/@drtimpearce

truths reverse longevity nichola pharmaceutical companies nuchido

S2 Ep40: The CP Podcast: Spiritual Warfare, Pharmaceutical Companies, & Eisenhower Treaty

The CP Podcast

Play Episode Listen Later Apr 24, 2024 57:33

What up! This week, we discuss spiritual work and the dark side that can come with it. We also discuss how the pharmaceutical companies control the media, Also the Eisenhower treaty. Have you heard of it? Always the questions.

spiritual warfare treaty dwight eisenhower pharmaceutical companies

Why Are leading Swiss Pharmaceutical Companies Investing in Slovenia?

Podcasts - SWI swissinfo.ch

Play Episode Listen Later Apr 23, 2024 16:26

Pharmaceutical giant Novartis invested billions in Slovenia, helping turn the country into a global player in generic drug production. Now, as cheap Asian competitors increasingly dominate the market, Swiss drug companies see the tiny Balkan nation playing a key role in their shift to more complex, expensive medicines.Articles and videos on Switzerland's investment in Slovenia are available on swissinfo.ch. For other science stories from Switzerland please go to www.swissinfo.ch/science.Journalist: Jessica Davis Plüss Host: Jo FahyAudio editor/video journalist: Céline Stegmüller & Michele AndinaDistribution and Marketing: Xin ZhangSWI swissinfo.ch is a public service media company based in Bern Switzerland. It publishes independent news and information in 10 languages about Switzerland for a global audience.

investing asian switzerland swiss balkans slovenia pharmaceutical novartis pharmaceutical companies bern switzerland

Dr. Peter McCullough (cardiologist, author)

Chuck Shute Podcast

Play Episode Listen Later Apr 5, 2024 53:18 Transcription Available

Dr. Peter McCullough is a cardiologist and author. He has broadly published on a range of topics in medicine with more than 1,000 publications and over 685 citations in the National Library of Medicine. We discuss the Covid-19 pandemic, treating long-covid and vaccine injuries, heart health, Avian bird flu and more. PLEASE CHECK WITH YOUR DOCTOR BEFORE MAKING ANY CHANGES TO YOUR HEALTH, DIET, MEDICATIONS, SUPPLEMENTS ETC. 00:00 - Intro 00:13 - Avian Bird Flu 01:35 - Measles 03:20 - Covid Vaccines Slight Risk 05:40 - Turbo Cancers 07:30 - Covid Viral Mutations 08:36 - Long Covid Symptoms 09:40 - McCullough Protocol 13:46 - Silent Hypoxemia 14:20 - Reactivation of Epstein-Barr & Lyme Disease 14:55- Polymyalgia Rheumatica & Covid Vaccines 16:00 - Doctors Being Unbiased 16:38 - Blood Clots & Embalmers 17:45 - Testing for Spike Protein 18:45 - Intermittent Fasting & Diet 24:10 - Magnesium & Vitamin D Supplements 25:00 - Ozempic, Ivermectin & Drugs 28:15 - Drug Protocol for Treating Covid30:05 - Politicians & Vaccine Response 35:45 - Natural Health & Pandemic Preparation 38:15 - FDA & Pharmaceutical Companies 39:40 - Vaccine Safety40:55 - Drug Companies, FDA Corruption & False Claims 44:20 - Covid Vaccines & Pregnant Women 45:40 - Testing for Spike Protein 47:25 - Patients with Covid Vaccine Injuries 48:00 - General Heart Health 51:30 - Follow Dr. McCullough 53:00 - Outro Dr. Peter McCullough website:https://www.petermcculloughmd.com/Chuck Shute link tree:https://linktr.ee/chuck_shuteSupport the showThanks for Listening & Shute for the Moon!

What Do You Do If You Can't Trust The Pharmaceutical Companies

The Michael Berry Show

Play Episode Listen Later Mar 12, 2024 49:55 Transcription Available

trust pharmaceutical companies

Madame Web - #807 Part 1

Jim and Them

Play Episode Listen Later Feb 25, 2024 97:01

Madame Web: Jim is back to report on his take of the much maligned Dakota Johnson release Madame Web! Did Sony pull it off!? Quaaludes: People just accept that ludes don't exist anymore but no one is asking the real question: WHY!? Also we should try them. Fantastic Four: The Fantastic Four cast has been officially confirmed, will this save the attitude around the MCU!? LET'S JUST TALK!, BOOGIE NIGHTS!, DON CHEADLE!, STREAMLINE THE CHATS?!, LINKTREE!, JUICE WORTH THE SQUEEZE!?, FREETARD!, PATREON!, FREE TIER!, SONY SPIDER-MAN MOVIES!, MADAME WEB!, MORBIUS!, VENOM!, CARNAGE!, LETTERBOXD!, FEED ME MORE!, BONKERS!, UNHINGED!, FUN BAD MOVIES!, TOM HARDY!, DAKOTA JOHNSON!, SPIDER PEOPLE!, SPIDER-GIRL!, SPIDER-WOMAN!, POWERS!, EZEKIAL SIMMS!, TERMINATOR!, TIME TRAVEL!, SYDNEY SWEENEY!, BIRDS OF PREY!, SPIDER TEAM!, AMAZON!, ADAM SCOTT!, BEN PARKER!, NSA!, BIG BROTHER!, DARK KNIGHT!, 2003!, BRITNEY SPEARS!, TOXIC!, PEPSI COLA!, PRODUCT PLACEMENT!, JURASSIC PARK!, GARETH EDWARDS!, JEFF'S BIRTHDAY!, WAWA HOODIE!, QUAALUDES!, DRUGS!, OUTLAWED!, CRIMINAL MASTERMIND!, JOKER!, ROBOTRIPPING!, AMBIEN!, WOLF OF WALL STREET!, FENTANYL!, THE BIG CHILL!, CLONOPIN!, XANAX!, JANKEM!, METHAQUALONE!, WAR ON DRUGS!, CRACK!, COCAINE!, PHARMACEUTICAL COMPANIES!, BIG PHARMA!, BASED DEPARTMENT!, DEATH BED!, PEDRO PASCAL!, FANTASTIC FOUR!, SAVIOR OF MARVEL!, VANESSA KIRBY!, DR. DOOM!, X-MEN!, MAGNETO!, MILES TELLER!, TIM STORY!, KUMAIL!, THE ETERNALS!, STEROIDS! You can find the videos from this episode at our Discord RIGHT HERE!

America's Roundtable with Gerard Gibert | The Rising Costs of Healthcare in America | Advancing Principled Solutions

America's Roundtable

Play Episode Listen Later Jan 30, 2024 42:45

Join America's Roundtable (https://americasrt.com/) radio co-hosts Natasha Srdoc and Joel Anand Samy with Gerard Gibert, entrepreneur, technologist, talk show host and founder and former CEO of Venture Technologies. The discussion focuses on key issues impacting America with an emphasis on the how the nation's rising health care costs are adversely affecting families, citizen-taxpayers, and private enterprises across the nation. In 1986, Mr. Gibert founded Venture Technologies, a technology and cloud services provider. As CEO of Venture, Mr. Gibert engineered numerous mergers and acquisitions of strategic targets, catapulting Venture to national prominence as a technology solutions provider. Initially funded at $189,000, Venture was sold for $92 million in 2019. Mr. Gibert serves on a variety of boards dedicated to growing Mississippi's economy. That list includes the Madison County Economic Development Authority, Madison County Business League and Foundation, Innovate Mississippi, Empower Mississippi, and the Mississippi Lottery Corporation. Gerard Gibert recently presented a compelling op-ed piece via SuperTalk.FM titled "We need out-of-the-box thinking to address Mississippi's healthcare woes." In a recent piece shared by Shakeel Ahmed, CEO at Atlas Surgical Group via Forbes in November 2023, the medical professional highlighted the following key statistics: In 2021, the nation's healthcare expenditure reached a staggering $4.3 trillion, accounting for 18.3% of the GDP, according to Centers for Medicare & Medicaid Services (CMS) data. In 2021, Americans spent an estimated $378 billion just on prescription drugs, as reported by Statista. This represents a substantial portion of overall healthcare spending, and the continuous increase in drug prices compounds the problem. The Kaiser Family Foundation found that the annual family premium for employer-sponsored health insurance plans surpassed $21,000 in 2020. americasrt.com (https://americasrt.com/) https://ileaderssummit.org/ | https://jerusalemleaderssummit.com/ America's Roundtable on Apple Podcasts: https://podcasts.apple.com/us/podcast/americas-roundtable/id1518878472 Twitter: @grgibert @ileaderssummit @AmericasRT @NatashaSrdoc @JoelAnandUSA @supertalk America's Roundtable is co-hosted by Natasha Srdoc and Joel Anand Samy, co-founders of International Leaders Summit and the Jerusalem Leaders Summit. America's Roundtable (https://americasrt.com/) radio program - a strategic initiative of International Leaders Summit, focuses on America's economy, healthcare reform, rule of law, security and trade, and its strategic partnership with rule of law nations around the world. The radio program features high-ranking US administration officials, cabinet members, members of Congress, state government officials, distinguished diplomats, business and media leaders and influential thinkers from around the world. Tune into America's Roundtable Radio program from Washington, DC via live streaming on Saturday mornings via 65 radio stations at 7:30 A.M. (ET) on Lanser Broadcasting Corporation covering the Michigan and the Midwest market, and at 7:30 A.M. (CT) on SuperTalk Mississippi — SuperTalk.FM reaching listeners in every county within the State of Mississippi, and neighboring states in the South including Alabama, Arkansas, Louisiana and Tennessee. Listen to America's Roundtable on digital platforms including Apple Podcasts, Spotify, Amazon, Google and other key online platforms. Listen live, Saturdays at 7:30 A.M. (CT) on SuperTalk | https://www.supertalk.fm

#2534 - Q&A: “Should I accept ads from pharmaceutical companies?”

Side Hustle School

Play Episode Listen Later Dec 9, 2023 7:33

Is it ethical for a health-focused podcast to accept sponsorships from online therapy and pharmaceutical companies? Side Hustle School features a new episode EVERY DAY, featuring detailed case studies of people who earn extra money without quitting their job. This year, the show includes free guided lessons and listener Q&A several days each week. Show notes: SideHustleSchool.com Email: team@sidehustleschool.com Be on the show: SideHustleSchool.com/questions Connect on Twitter: @chrisguillebeau Connect on Instagram: @193countries Visit Chris's main site: ChrisGuillebeau.com If you're enjoying the show, please pass it along! It's free and has been published every single day since January 1, 2017. We're also very grateful for your five-star ratings—it shows that people are listening and looking forward to new episodes.

accept chris guillebeau pharmaceutical companies side hustle school

The opioid crisis: From pill mills to the rise of fentanyl, and current glimmers of hope

Tiny Matters

Play Episode Listen Later Nov 15, 2023 30:38

In 2021, 80,411 people in the United States died of an overdose involving opioids, making up 75% of all drug overdose deaths that year. That's also 10 times as many opioid overdose deaths as in 1999. How did we get here?In this episode, Sam and Deboki trace the origins of opioids, from opium and morphine to fentanyl, and scrutinize the significant role pharmaceutical companies played in kick starting the opioid crisis in the 1990s. Today, the highly potent opioid fentanyl has become the street supply of opioids, which has led to a steep incline in overdose deaths. On top of that, it can be adulterated with dangerous substances like xylazine or "tranq." Now more than ever, facilities focused on harm reduction are crucial. These facilities allow for safe needle exchange, which reduces the risk of transmitting diseases like HIV and hepatitis C, and also provide opioid users with treatment and access to other healthcare testing.Although the opioid crisis is a tragic reality in this country, harm reduction, increased opioid research funding, and hefty pharmaceutical company payouts are providing glimmers of hope.In the US, the Substance Abuse and Mental Health Services Administration (SAMHSA) has a National Helpline for individuals and family members facing mental and/or substance use disorders. It can be reached at 1-800-662-HELP (1-800-662-4357). It is confidential, free, in both English and Spanish, and open 24/7, 365 days a year. The helpline provides referrals to local treatment facilities, support groups, and community-based organizations. Links to the Tiny Show & Tell stories are here and here. Pick up a Tiny Matters mug here! All Tiny Matters transcripts are available here.

The Tudor Dixon Podcast: Corruption, Collusion, and Cover-ups with Senator Ron Johnson

Play Episode Listen Later Nov 3, 2023 31:34 Transcription Available

In this episode, Tudor interviews Senator Ron Johnson about corruption allegations against Joe Biden and his family's business dealings. They discuss the FBI's handling of the investigation, the role of the media, and the impact of policies on the manufacturing industry and national security. Senator Johnson criticizes the FBI and the media for their handling of the situation. They also discuss environmental issues, climate change, and the importance of grassroots campaigning. The conversation also covers the conflict between Russia and Ukraine, border security, and the safety and side effects of COVID-19 vaccines. The Tudor Dixon Podcast is part of the Clay Travis & Buck Sexton Podcast Network - new episodes debut every Monday, Wednesday, & Friday. For more information visit TudorDixonPodcast.comFollow Clay & Buck on YouTube: https://www.youtube.com/c/clayandbuckSee omnystudio.com/listener for privacy information.

The Tudor Dixon Podcast: Corruption, Collusion, and Cover-ups with Senator Ron Johnson

Play Episode Listen Later Nov 3, 2023 31:34 Transcription Available

In this episode, Tudor interviews Senator Ron Johnson about corruption allegations against Joe Biden and his family's business dealings. They discuss the FBI's handling of the investigation, the role of the media, and the impact of policies on the manufacturing industry and national security. Senator Johnson criticizes the FBI and the media for their handling of the situation. They also discuss environmental issues, climate change, and the importance of grassroots campaigning. The conversation also covers the conflict between Russia and Ukraine, border security, and the safety and side effects of COVID-19 vaccines. The Tudor Dixon Podcast is part of the Clay Travis & Buck Sexton Podcast Network - new episodes debut every Monday, Wednesday, & Friday. For more information visit TudorDixonPodcast.comSee omnystudio.com/listener for privacy information.

The Tudor Dixon Podcast: Corruption, Collusion, and Cover-ups with Senator Ron Johnson

The Tudor Dixon Podcast

Play Episode Listen Later Nov 3, 2023 31:34 Transcription Available

In this episode, Tudor interviews Senator Ron Johnson about corruption allegations against Joe Biden and his family's business dealings. They discuss the FBI's handling of the investigation, the role of the media, and the impact of policies on the manufacturing industry and national security. Senator Johnson criticizes the FBI and the media for their handling of the situation. They also discuss environmental issues, climate change, and the importance of grassroots campaigning. The conversation also covers the conflict between Russia and Ukraine, border security, and the safety and side effects of COVID-19 vaccines. The Tudor Dixon Podcast is part of the Clay Travis & Buck Sexton Podcast Network - new episodes debut every Monday, Wednesday, & Friday. For more information visit TudorDixonPodcast.comSee omnystudio.com/listener for privacy information.

Flattening the Curve of Healthcare Cost | James Maskell

The Lindsey Elmore Show

Play Episode Listen Later Oct 17, 2023 45:48

On a mission to flatten the curve of healthcare costs, James Maskell has spent the past decade innovating at the cross section of functional medicine and community. To that end, he created the Functional Forum, the world's largest integrative medicine conference with record-setting participation online and growing physician communities around the world. His organization and best selling book of the same name, Evolution of Medicine, prepares health professionals for this new era of personalized, participatory medicine. His new project, HealCommunity, follows his second book "The Community Cure", makes it easy for clinics and health systems to deliver lifestyle focused care effectively and frictionlessly. He is an in demand speaker and impresario, being featured on TEDMED, HuffPostLive and TEDx, as well as lecturing internationally. He lives in the Sierra Nevadas with his wife and two daughters. Topics covered in this episode:Healthcare SystemsPharmaceutical-First Approach in Medical CareThe Impact of Pharmaceutical Companies on HealthcareHealth Metrics and Chronic IllnessCost of Healthcare in AmericaThe National Health Service (NHS) in the UKBenefits and Drawbacks of the NHSLack of Innovation in the UK Healthcare SystemChallenges in the Healthcare SystemsGovernmental Oversight of Drug PricingThe Need for Shifting Healthcare PracticesThe Role of Community in Health and WellnessCapitation as a Payment Model in HealthcareThe Evolving Role of Pharmacists in Healthcare DeliveryTo learn more about James Maskell and his work, head over to https://www.jamesmaskell.com/ & https://thecommunitycure.com/audioIG @mrjamesmaskell__________________________________________________________Happiness is now available on the go! The Happy Juice Pack is now available with MentaBiotics, Energy+ & Amare EDGE all in easy to carry stick packs. Head to http://www.lindseyelmore.com/amare to save $10 on your Amare Happy Juice Pack. __________________________________________________________Kids Calm is officially here and it is time to stop fighting sleep and build better relaxation and wind down routines. You can get a two pack of Kids Calm or you can check out the Laid-Back Kids Pack, which contains Kids Calm as well. Head to http://www.lindseyelmore.com/amare to save $10 on your first order!____________________________________________________________________________________________________________________We hope you enjoyed this episode. Come check us out at www.lindseyelmore.com/podcast.This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/5952903/advertisement

Flattening the Curve of Healthcare Cost | James Maskell

The Lindsey Elmore Show

Play Episode Listen Later Oct 17, 2023 45:47

On a mission to flatten the curve of healthcare costs, James Maskell has spent the past decade innovating at the cross section of functional medicine and community. To that end, he created the Functional Forum, the world's largest integrative medicine conference with record-setting participation online and growing physician communities around the world. His organization and best selling book of the same name, Evolution of Medicine, prepares health professionals for this new era of personalized, participatory medicine. His new project, HealCommunity, follows his second book "The Community Cure", makes it easy for clinics and health systems to deliver lifestyle focused care effectively and frictionlessly. He is an in demand speaker and impresario, being featured on TEDMED, HuffPostLive and TEDx, as well as lecturing internationally. He lives in the Sierra Nevadas with his wife and two daughters. Topics covered in this episode:Healthcare Systems Pharmaceutical-First Approach in Medical CareThe Impact of Pharmaceutical Companies on HealthcareHealth Metrics and Chronic IllnessCost of Healthcare in AmericaThe National Health Service (NHS) in the UKBenefits and Drawbacks of the NHSLack of Innovation in the UK Healthcare SystemChallenges in the Healthcare SystemsGovernmental Oversight of Drug PricingThe Need for Shifting Healthcare PracticesThe Role of Community in Health and WellnessCapitation as a Payment Model in HealthcareThe Evolving Role of Pharmacists in Healthcare DeliveryTo learn more about James Maskell and his work, head over to https://www.jamesmaskell.com/IG @mrjamesmaskell__________________________________________________________Happiness is now available on the go! The Happy Juice Pack is now available with MentaBiotics, Energy+ & Amare EDGE all in easy to carry stick packs. Head to http://www.lindseyelmore.com/amare to save $10 on your Amare Happy Juice Pack. __________________________________________________________Kids Calm is officially here and it is time to stop fighting sleep and build better relaxation and wind down routines. You can get a two pack of Kids Calm or you can check out the Laid-Back Kids Pack, which contains Kids Calm as well. Head to http://www.lindseyelmore.com/amare to save $10 on your first order! ____________________________________________________________________________________________________________________We hope you enjoyed this episode. Come check us out at www.lindseyelmore.com/podcast.

The Tudor Dixon Podcast: One on One with Nikki Haley

united states america china education mexico doctors war russia chinese joe biden ukraine congress hospitals iran iowa values south carolina enemy kamala harris taiwan united nations volunteers transparency new hampshire north korea terrorists dixon national security fentanyl one on one osama bin laden healthcare system nikki haley apprenticeships tudor greg abbott upcoming events border crisis insurance companies special operations infiltration cartels national debt sanctuary cities podcastone illegal immigrants border protection foreign aid government spending parental controls clay travis border control chinese companies american universities special operations forces drone technology european countries pharmaceutical companies elissa slotkin pharmacy benefit managers tudor dixon hypersonic missiles us soil south carolina governor

Play Episode Listen Later Sep 13, 2023 29:31 Transcription Available

In this episode, Tudor welcomes Nikki Haley as a guest. They discuss various topics including border control, the influence of cartels, and Haley's proposals to address the border crisis. They also delve into Haley's experience as ambassador to the United Nations, focusing on promoting America's interests and values. The conversation then shifts to the threat posed by China, including their infiltration into the US and military buildup. Haley also addresses the issue of members of Congress signing non-disclosure agreements with Chinese companies and emphasizes the need to protect national security. Other topics discussed include government spending, education reform, and healthcare transparency. The Tudor Dixon Podcast is part of the Clay Travis & Buck Sexton Podcast Network - new episodes debut every Monday, Wednesday, & Friday. For more info visit TudorDixonPodcast.comFollow Clay & Buck on YouTube: https://www.youtube.com/c/clayandbuckSee omnystudio.com/listener for privacy information.

The Tudor Dixon Podcast: One on One with Nikki Haley

united states america china education mexico doctors war russia chinese joe biden ukraine congress hospitals iran iowa values south carolina enemy kamala harris taiwan united nations volunteers transparency new hampshire north korea terrorists dixon national security fentanyl one on one osama bin laden healthcare system nikki haley apprenticeships tudor greg abbott upcoming events border crisis insurance companies special operations infiltration cartels national debt sanctuary cities podcastone illegal immigrants border protection foreign aid government spending parental controls clay travis border control chinese companies american universities special operations forces drone technology european countries pharmaceutical companies elissa slotkin pharmacy benefit managers tudor dixon hypersonic missiles us soil south carolina governor

Play Episode Listen Later Sep 13, 2023 29:31 Transcription Available

In this episode, Tudor welcomes Nikki Haley as a guest. They discuss various topics including border control, the influence of cartels, and Haley's proposals to address the border crisis. They also delve into Haley's experience as ambassador to the United Nations, focusing on promoting America's interests and values. The conversation then shifts to the threat posed by China, including their infiltration into the US and military buildup. Haley also addresses the issue of members of Congress signing non-disclosure agreements with Chinese companies and emphasizes the need to protect national security. Other topics discussed include government spending, education reform, and healthcare transparency. The Tudor Dixon Podcast is part of the Clay Travis & Buck Sexton Podcast Network - new episodes debut every Monday, Wednesday, & Friday. For more info visit TudorDixonPodcast.comSee omnystudio.com/listener for privacy information.

The Truth with Lisa Boothe: The Money Behind Transitioning Children

The Truth with Lisa Boothe

Play Episode Listen Later Sep 7, 2023 25:37 Transcription Available

In this podcast episode, Lisa interviews Chloe Cole, a detransitioned individual, who shares her personal journey of transitioning as a child and the challenges she faced. Chloe discusses the lack of support during her detransition and the financial motivations behind transgender surgeries. She emphasizes the importance of exploring oneself and not rushing into life-altering decisions at a young age. Chloe also shares her passion for art and her desire to pursue fashion design as a career. The Truth with Lisa Boothe is part of the iHeartRadio Podcast Network - new episodes debut every Monday & Thursday.Follow Clay & Buck on YouTube: https://www.youtube.com/c/clayandbuckSee omnystudio.com/listener for privacy information.

The Truth with Lisa Boothe: The Money Behind Transitioning Children

Play Episode Listen Later Sep 7, 2023 25:37 Transcription Available

In this podcast episode, Lisa interviews Chloe Cole, a detransitioned individual, who shares her personal journey of transitioning as a child and the challenges she faced. Chloe discusses the lack of support during her detransition and the financial motivations behind transgender surgeries. She emphasizes the importance of exploring oneself and not rushing into life-altering decisions at a young age. Chloe also shares her passion for art and her desire to pursue fashion design as a career. The Truth with Lisa Boothe is part of the iHeartRadio Podcast Network - new episodes debut every Monday & Thursday.See omnystudio.com/listener for privacy information.

The Tudor Dixon Podcast: An Exclusive Interview with President Donald Trump

Play Episode Listen Later Aug 30, 2023 21:19 Transcription Available

In this episode, Tudor welcomes President Donald Trump to discuss various topics. Dixon highlights Trump's acts of kindness, such as visiting sick individuals and leaving gifts for soldiers. Trump acknowledges the media's lack of interest in these stories and expresses his respect for soldiers and their sacrifices. They also discuss Trump's role as a father and his views on the weaponization of government. The conversation covers topics like the fake dossier, COVID-19, border security, and the impact of electric vehicles. Trump emphasizes the need for transparency, common-sense solutions, and support for families. The Tudor Dixon Podcast is part of the Clay Travis & Buck Sexton Podcast Network - new episodes debut every Monday, Wednesday, & Friday. For more information visit TudorDixoPodcast.comFollow Clay & Buck on YouTube: https://www.youtube.com/c/clayandbuckSee omnystudio.com/listener for privacy information.

The Tudor Dixon Podcast: An Exclusive Interview with President Donald Trump

Play Episode Listen Later Aug 30, 2023 21:19 Transcription Available

In this episode, Tudor welcomes President Donald Trump to discuss various topics. Dixon highlights Trump's acts of kindness, such as visiting sick individuals and leaving gifts for soldiers. Trump acknowledges the media's lack of interest in these stories and expresses his respect for soldiers and their sacrifices. They also discuss Trump's role as a father and his views on the weaponization of government. The conversation covers topics like the fake dossier, COVID-19, border security, and the impact of electric vehicles. Trump emphasizes the need for transparency, common-sense solutions, and support for families. The Tudor Dixon Podcast is part of the Clay Travis & Buck Sexton Podcast Network - new episodes debut every Monday, Wednesday, & Friday. For more information visit TudorDixoPodcast.comSee omnystudio.com/listener for privacy information.

The Tudor Dixon Podcast: Unmasking the Truth: The Lack of Transparency in COVID-19 Vaccines

Play Episode Listen Later Jun 28, 2023 30:48

Are you curious about the lack of transparency surrounding COVID-19 vaccines? Do you want to know why it's important to have access to all the information before making a decision? In this episode of the Tudor Dixon Podcast, Tudor sits down with Dr. Alaa Abd-Elsayed, Medical Director at the University of Wisconsin Pain Clinic, to discuss the importance of transparency and informed decision-making when it comes to health. They dive into the lack of data disclosure, the impact of the pandemic on children's health, and the opioid epidemic. Dr. Abd-Elsayed emphasizes the need for open discussions and the availability of data to ensure the public's well-being. The Tudor Dixon Podcast is part of the Clay Travis & Buck Sexton Podcast Network - new episodes debut every Monday, Wednesday, & Friday. For more info visit TudorDixonPodcast.comFollow Clay & Buck on YouTube: https://www.youtube.com/c/clayandbuckSee omnystudio.com/listener for privacy information.

The Tudor Dixon Podcast: Unmasking the Truth: The Lack of Transparency in COVID-19 Vaccines